{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:17:53Z","timestamp":1792804673723,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High-grade serous ovarian cancer (HG-SOC)\u2014often referred to as a \u201csilent killer\u201d\u2014is the most lethal gynecological malignancy. The fallopian tube (murine oviduct) and ovarian surface epithelium (OSE) are considered the main candidate tissues of origin of this cancer. However, the relative contribution of each tissue to HG-SOC is not yet clear. Here, we establish organoid-based tumor progression models of HG-SOC from murine oviductal and OSE tissues. We use CRISPR-Cas9 genome editing to introduce mutations into genes commonly found mutated in HG-SOC, such as <jats:italic>Trp53<\/jats:italic>, <jats:italic>Brca1<\/jats:italic>, <jats:italic>Nf1<\/jats:italic> and <jats:italic>Pten<\/jats:italic>. Our results support the dual origin hypothesis of HG-SOC, as we demonstrate that both epithelia can give rise to ovarian tumors with high-grade pathology. However, the mutated oviductal organoids expand much faster in vitro and more readily form malignant tumors upon transplantation. Furthermore, in vitro drug testing reveals distinct lineage-dependent sensitivities to the common drugs used to treat HG-SOC in patients.<\/jats:p>","DOI":"10.1038\/s41467-020-16432-0","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T10:03:12Z","timestamp":1590573792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids"],"prefix":"10.1038","volume":"11","author":[{"given":"Kadi","family":"L\u00f5hmussaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oded","family":"Kopper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Korving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Begthel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celien P. H.","family":"Vreuls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan H.","family":"van Es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3077-5582","authenticated-orcid":false,"given":"Hans","family":"Clevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"16432_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","volume":"108","author":"DM Gershenson","year":"2006","unstructured":"Gershenson, D. M. et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet. Gynecol. 108, 361\u2013368 (2006).","journal-title":"Obstet. Gynecol."},{"key":"16432_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/jcb.240590928","volume":"23","author":"RE Scully","year":"1995","unstructured":"Scully, R. E. Pathology of ovarian cancer precursors. J. Cell Biochem. Suppl. 23, 208\u2013218 (1995).","journal-title":"J. Cell Biochem. Suppl."},{"key":"16432_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0140-6736(71)92335-X","volume":"2","author":"MF Fathalla","year":"1971","unstructured":"Fathalla, M. F. Incessant ovulation\u2014a factor in ovarian neoplasia? Lancet 2, 163 (1971).","journal-title":"Lancet"},{"key":"16432_CR4","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/01.pas.0000202161.80739.ac","volume":"30","author":"ML Carcangiu","year":"2006","unstructured":"Carcangiu, M. L. et al. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am. J. Surg. Pathol. 30, 1222\u20131230 (2006).","journal-title":"Am. J. Surg. Pathol."},{"key":"16432_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.2005.04.109","volume":"23","author":"CB Powell","year":"2005","unstructured":"Powell, C. B. et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J. Clin. Oncol. 23, 127\u2013132 (2005).","journal-title":"J. Clin. Oncol."},{"key":"16432_CR6","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1200\/JCO.2007.12.2622","volume":"25","author":"MJ Callahan","year":"2007","unstructured":"Callahan, M. J. et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J. Clin. Oncol. 25, 3985\u20133990 (2007).","journal-title":"J. Clin. Oncol."},{"key":"16432_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research, N.","year":"2011","unstructured":"Cancer Genome Atlas Research, N. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609\u2013615 (2011).","journal-title":"Nature"},{"key":"16432_CR8","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/ng.2762","volume":"45","author":"G Ciriello","year":"2013","unstructured":"Ciriello, G. et al. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127\u20131133 (2013).","journal-title":"Nat. Genet."},{"key":"16432_CR9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/carcin\/bgp007","volume":"30","author":"R Sasaki","year":"2009","unstructured":"Sasaki, R. et al. Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes. Carcinogenesis 30, 423\u2013431 (2009).","journal-title":"Carcinogenesis"},{"key":"16432_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1158\/0008-5472.CAN-10-2550","volume":"71","author":"J Wu","year":"2011","unstructured":"Wu, J. et al. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res. 71, 349\u2013359 (2011).","journal-title":"Cancer Res."},{"key":"16432_CR11","doi-asserted-by":"publisher","first-page":"e8534","DOI":"10.1371\/journal.pone.0008534","volume":"4","author":"KV Clark-Knowles","year":"2009","unstructured":"Clark-Knowles, K. V., Senterman, M. K., Collins, O. & Vanderhyden, B. C. Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas. PLoS ONE 4, e8534 (2009).","journal-title":"PLoS ONE"},{"key":"16432_CR12","doi-asserted-by":"publisher","first-page":"8949","DOI":"10.1158\/0008-5472.CAN-06-1495","volume":"66","author":"D Xing","year":"2006","unstructured":"Xing, D. & Orsulic, S. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res. 66, 8949\u20138953 (2006).","journal-title":"Cancer Res."},{"key":"16432_CR13","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1158\/0008-5472.CAN-11-3834","volume":"72","author":"L Szabova","year":"2012","unstructured":"Szabova, L. et al. Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res. 72, 4141\u20134153 (2012).","journal-title":"Cancer Res."},{"key":"16432_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/path.4353","volume":"233","author":"CA Sherman-Baust","year":"2014","unstructured":"Sherman-Baust, C. A. et al. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J. Pathol. 233, 228\u2013237 (2014).","journal-title":"J. Pathol."},{"key":"16432_CR15","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","volume":"24","author":"R Perets","year":"2013","unstructured":"Perets, R. et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24, 751\u2013765 (2013).","journal-title":"Cancer Cell"},{"key":"16432_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/path.4927","volume":"243","author":"Y Zhai","year":"2017","unstructured":"Zhai, Y. et al. High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease. J. Pathol. 243, 16\u201325 (2017).","journal-title":"J. Pathol."},{"key":"16432_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01217-9","volume":"8","author":"J Ducie","year":"2017","unstructured":"Ducie, J. et al. Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nat. Commun. 8, 990 (2017).","journal-title":"Nat. Commun."},{"key":"16432_CR18","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1016\/j.celrep.2019.10.122","volume":"29","author":"K Lawrenson","year":"2019","unstructured":"Lawrenson, K. et al. A study of high-grade serous ovarian cancer origins implicates the SOX18 transcription factor in tumor development. Cell Rep. 29, 3726\u20133735 e3724 (2019).","journal-title":"Cell Rep."},{"key":"16432_CR19","doi-asserted-by":"publisher","first-page":"7400","DOI":"10.1158\/1078-0432.CCR-17-0638","volume":"23","author":"D Hao","year":"2017","unstructured":"Hao, D. et al. Integrated analysis reveals tubal- and ovarian-originated serous ovarian cancer and predicts differential therapeutic responses. Clin. Cancer Res. 23, 7400\u20137411 (2017).","journal-title":"Clin. Cancer Res."},{"key":"16432_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12645","volume":"7","author":"F Coscia","year":"2016","unstructured":"Coscia, F. et al. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat. Commun. 7, 12645 (2016).","journal-title":"Nat. Commun."},{"key":"16432_CR21","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1158\/2159-8290.CD-16-0607","volume":"6","author":"MA Eckert","year":"2016","unstructured":"Eckert, M. A. et al. Genomics of ovarian cancer progression reveals diverse metastatic trajectories including intraepithelial metastasis to the fallopian tube. Cancer Disco. 6, 1342\u20131351 (2016).","journal-title":"Cancer Disco."},{"key":"16432_CR22","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/jamaoncol.2015.1618","volume":"1","author":"AS McDaniel","year":"2015","unstructured":"McDaniel, A. S. et al. Next-generation sequencing of tubal intraepithelial carcinomas. JAMA Oncol. 1, 1128\u20131132 (2015).","journal-title":"JAMA Oncol."},{"key":"16432_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nature11979","volume":"495","author":"A Flesken-Nikitin","year":"2013","unstructured":"Flesken-Nikitin, A. et al. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature 495, 241\u2013245 (2013).","journal-title":"Nature"},{"key":"16432_CR24","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/ncb3000","volume":"16","author":"A Ng","year":"2014","unstructured":"Ng, A. et al. Lgr5 marks stem\/progenitor cells in ovary and tubal epithelia. Nat. Cell Biol. 16, 745\u2013757 (2014).","journal-title":"Nat. Cell Biol."},{"key":"16432_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1290\/1071-2690(2000)036<0657:ESOOSE>2.0.CO;2","volume":"36","author":"W Bai","year":"2000","unstructured":"Bai, W., Oliveros-Saunders, B., Wang, Q., Acevedo-Duncan, M. E. & Nicosia, S. V. Estrogen stimulation of ovarian surface epithelial cell proliferation. Vitr. Cell Dev. Biol. Anim. 36, 657\u2013666 (2000).","journal-title":"Vitr. Cell Dev. Biol. Anim."},{"key":"16432_CR26","first-page":"255","volume":"22","author":"N Auersperg","year":"2001","unstructured":"Auersperg, N., Wong, A. S., Choi, K. C., Kang, S. K. & Leung, P. C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22, 255\u2013288 (2001).","journal-title":"Endocr. Rev."},{"key":"16432_CR27","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1242\/dev.149989","volume":"144","author":"A Ghosh","year":"2017","unstructured":"Ghosh, A., Syed, S. M. & Tanwar, P. S. In vivo genetic cell lineage tracing reveals that oviductal secretory cells self-renew and give rise to ciliated cells. Development 144, 3031\u20133041 (2017).","journal-title":"Development"},{"key":"16432_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9989","volume":"6","author":"M Kessler","year":"2015","unstructured":"Kessler, M. et al. The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids. Nat. Commun. 6, 8989 (2015).","journal-title":"Nat. Commun."},{"key":"16432_CR29","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.humpath.2015.03.017","volume":"46","author":"E Adler","year":"2015","unstructured":"Adler, E., Mhawech-Fauceglia, P., Gayther, S. A. & Lawrenson, K. PAX8 expression in ovarian surface epithelial cells. Hum. Pathol. 46, 948\u2013956 (2015).","journal-title":"Hum. Pathol."},{"key":"16432_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fonc.2014.00053","volume":"4","author":"CW McCloskey","year":"2014","unstructured":"McCloskey, C. W. et al. A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population. Front Oncol. 4, 53 (2014).","journal-title":"Front Oncol."},{"key":"16432_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/path.2091","volume":"211","author":"Y Lee","year":"2007","unstructured":"Lee, Y. et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 211, 26\u201335 (2007).","journal-title":"J. Pathol."},{"key":"16432_CR32","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/path.1000","volume":"195","author":"JM Piek","year":"2001","unstructured":"Piek, J. M. et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 195, 451\u2013456 (2001).","journal-title":"J. Pathol."},{"key":"16432_CR33","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/path.3023","volume":"226","author":"E Kuhn","year":"2012","unstructured":"Kuhn, E. et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma\u2013evidence supporting the clonal relationship of the two lesions. J. Pathol. 226, 421\u2013426 (2012).","journal-title":"J. Pathol."},{"key":"16432_CR34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","volume":"31","author":"DW Kindelberger","year":"2007","unstructured":"Kindelberger, D. W. et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am. J. Surg. Pathol. 31, 161\u2013169 (2007).","journal-title":"Am. J. Surg. Pathol."},{"key":"16432_CR35","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","volume":"521","author":"AM Patch","year":"2015","unstructured":"Patch, A. M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489\u2013494 (2015).","journal-title":"Nature"},{"key":"16432_CR36","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","volume":"159","author":"RJ Platt","year":"2014","unstructured":"Platt, R. J. et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159, 440\u2013455 (2014).","journal-title":"Cell"},{"key":"16432_CR37","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844\u2013848 (2004).","journal-title":"Science"},{"key":"16432_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8505","volume":"6","author":"M Sedic","year":"2015","unstructured":"Sedic, M. et al. Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence. Nat. Commun. 6, 7505 (2015).","journal-title":"Nat. Commun."},{"key":"16432_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature14415","volume":"521","author":"J Drost","year":"2015","unstructured":"Drost, J. et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature 521, 43\u201347 (2015).","journal-title":"Nature"},{"key":"16432_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4361","volume":"5","author":"G Peng","year":"2014","unstructured":"Peng, G. et al. Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat. Commun. 5, 3361 (2014).","journal-title":"Nat. Commun."},{"key":"16432_CR41","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198\u20135208 (2008).","journal-title":"Clin. Cancer Res."},{"key":"16432_CR42","doi-asserted-by":"publisher","unstructured":"Konecny, G. E. et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J. Natl Cancer Inst. 106 https:\/\/doi.org\/10.1093\/jnci\/dju249 (2014).","DOI":"10.1093\/jnci\/dju249"},{"key":"16432_CR43","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.cell.2018.11.013","volume":"175","author":"H Hu","year":"2018","unstructured":"Hu, H. et al. Long-term expansion of functional mouse and human hepatocytes as 3D organoids. Cell 175, 1591\u20131606 e1519 (2018).","journal-title":"Cell"},{"key":"16432_CR44","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.stem.2016.11.001","volume":"20","author":"O Basak","year":"2017","unstructured":"Basak, O. et al. Induced quiescence of Lgr5+ stem cells in intestinal organoids enables differentiation of hormone-producing enteroendocrine cells. Cell Stem Cell 20, 177\u2013190 e174 (2017).","journal-title":"Cell Stem Cell"},{"key":"16432_CR45","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","volume":"25","author":"O Kopper","year":"2019","unstructured":"Kopper, O. et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat. Med. 25, 838\u2013849 (2019).","journal-title":"Nat. Med."},{"key":"16432_CR46","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs, N. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373\u2013386 e310 (2018).","journal-title":"Cell"},{"key":"16432_CR47","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","volume":"161","author":"M van de Wetering","year":"2015","unstructured":"van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933\u2013945 (2015).","journal-title":"Cell"},{"key":"16432_CR48","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nm.3802","volume":"21","author":"M Matano","year":"2015","unstructured":"Matano, M. et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat. Med. 21, 256\u2013262 (2015).","journal-title":"Nat. Med."},{"key":"16432_CR49","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","volume":"160","author":"SF Boj","year":"2015","unstructured":"Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324\u2013338 (2015).","journal-title":"Cell"},{"key":"16432_CR50","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.stem.2019.04.017","volume":"24","author":"B Artegiani","year":"2019","unstructured":"Artegiani, B. et al. Probing the tumor suppressor function of BAP1 in CRISPR-engineered human liver organoids. Cell Stem Cell 24, 927\u2013943 e926 (2019).","journal-title":"Cell Stem Cell"},{"key":"16432_CR51","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1126\/science.aaw6985","volume":"364","author":"D Tuveson","year":"2019","unstructured":"Tuveson, D. & Clevers, H. Cancer modeling meets human organoid technology. Science 364, 952\u2013955 (2019).","journal-title":"Science"},{"key":"16432_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13116-2","volume":"10","author":"S Zhang","year":"2019","unstructured":"Zhang, S. et al. Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma. Nat. Commun. 10, 5367 (2019).","journal-title":"Nat. Commun."},{"key":"16432_CR53","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S0092-8674(00)81302-1","volume":"85","author":"R Hakem","year":"1996","unstructured":"Hakem, R. et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85, 1009\u20131023 (1996).","journal-title":"Cell"},{"key":"16432_CR54","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/ng0296-191","volume":"12","author":"LC Gowen","year":"1996","unstructured":"Gowen, L. C., Johnson, B. L., Latour, A. M., Sulik, K. K. & Koller, B. H. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat. Genet. 12, 191\u2013194 (1996).","journal-title":"Nat. Genet."},{"key":"16432_CR55","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16432-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16432-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16432-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T22:27:17Z","timestamp":1670279237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16432-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["16432"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-16432-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"assertion":[{"value":"23 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.C. is an inventor on several patents involving the adult stem cell-based organoid technology. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2660"}}